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SUMMARY. Detailed, country-specific epidemiological data
are needed to characterize the burden of chronic hepatitis C
virus (HCV) infection around the world. With new treatment
options available, policy makers and public health officials
must reconsider national strategies for infection control. In
this study of 15 countries, published and unpublished data
on HCV prevalence, viraemia, genotype, age and gender
distribution, liver transplants and diagnosis and treatment
rates were gathered from the literature and validated by
expert consensus in each country. Viraemic prevalence in
this study ranged from 0.2% in Iran and Lebanon to 4.2% in
Pakistan. The largest viraemic populations were in Pakistan
(7 001 000 cases) and Indonesia (3 187 000 cases). Injec-
tion drug use (IDU) and a historically unsafe blood supply
were major risk factors in most countries. Diagnosis, treat-
ment and liver transplant rates varied widely between coun-
tries. However, comparison across countries was difficult as
the number of cases changes over time. Access to reliable
data on measures such as these is critical for the develop-
ment of future strategies to manage the disease burden.
Abbreviations: G, genotype; HCV, hepatitis C virus; IDU, injection drug use; Peg-IFN, pegylated interferon; RBV, ribavirin; RNA, ribonucleic
acid; UN, United Nations.
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INTRODUCTION
Hepatitis C virus (HCV) infection is a global public health
burden, causing an increasing level of liver-related morbid-
ity and mortality due to the disease progression of an age-
ing-prevalent population [1–6]. The HCV disease paradigm
varies by country based on historical and present risk fac-
tors, screening programmes and treatment rates. Individual
countries must consider appropriate country-specific pre-
vention, diagnosis and treatment strategies to reduce the
disease burden represented by HCV. Unfortunately, in
many countries, there is a lack of robust epidemiological
data upon which to base these strategies. Many studies
have examined regional HCV infection rates [7–12], but
they have typically focused on quantifying the anti-HCV
prevalence. This study is a continuation of a project to
quantify global HCV epidemiology in a systematic manner.
The aim of this study was to develop consensus estimates,
using the best available published and unpublished data,
for the total number of viraemic infections [HCV ribonu-
cleic acid (RNA) positive], the total number of viraemic-di-
agnosed individuals, the number of viraemic newly
diagnosed, annual number of treated patients and the
number of liver transplants attributed to HCV in each
country. The countries were selected based on the avail-
ability of published data and the willingness to collaborate.
Other countries are being analysed and will be published
separately.
METHODOLOGY
A systematic review of the literature was conducted to
identify studies reporting the total number of HCV cases
diagnosed, treated and cured in each country of interest.
The review encompassed all studies between January 1990
and December 2014. Indexed articles were found by
searching PubMed and Embase. Nonindexed sources were
identified through individual countries’ Ministry of Health
websites and international agencies’ reports. In addition,
an expert panel in each country provided proceedings of
local conferences, unpublished data and data from large
liver centres that could be extrapolated to the national
level.
Face-to-face meetings were conducted to review findings
and analyses with the expert panel. When no input data
were available, analogues (data from countries with a simi-
lar healthcare practice and/or risk factors) or expert inputs
were used. Ranges were chosen to capture uncertainty in
inputs, with wider ranges implying greater uncertainty.
Viraemic infections represented current RNA-positive
HCV or chronic HCV infections. The term viraemic was
used throughout this study to highlight the presence of
HCV virus. The term new infections was used for acute
infections among immigrants entering the country. The
term incidence was used for acute infections and not newly
diagnosed. Care was taken to collect and list the year of
the reported collection as the data were reported over a
wide range of years. As shown in the next publication in
this supplement [13], a modelling approach was used to
estimate the HCV-infected populations (viraemic, diagnosed
and treated) in 2014. Unless stated, population data were
obtained from the United Nations’ (UN) population data-
base by age, gender and five-year age-cohort [14].
The annual number of liver transplants was gathered
from national or international databases and adjusted for
the percentage attributed to HCV. The number of anti-
body-positive and RNA-positive diagnosed cases was gath-
ered from national databases, use of analogues or expert
panel input. It was explicitly stated when published or offi-
cial data were not available. In countries where HCV was
a notifiable infection and a reliable annual number of
newly diagnosed cases were reported, the total of diag-
nosed cases was calculated by summing data from all years
after taking into consideration the mortality among the
diagnosed cases. In countries where the number of total
and newly diagnosed cases was not available, expert panel
input was used. Diagnosis rates from the known countries
(analogues) were provided to the expert panel, and the
panel selected one or more countries that had similar pro-
files. It was assumed that the viraemic rate among the
diagnosed population was the same as the total infected
population, and the same viraemic rate was used to esti-
mate the number of viraemic-diagnosed individuals.
Two methods were used to estimate the total number of
treated HCV-infected patients. In countries where reliable
national data were available, the reported numbers were
used. In other countries, the annual number of units of
pegylated interferon (Peg-IFN) or ribavirin (RBV) sold, as
reported by IMS Health [15], were converted to treated
patients using the average number of units per patient.
The average number of units per patient was calculated
using the genotype distribution of the infected population
(assumed the genotype distribution of the treated popula-
tion was the same as the overall population), the duration
of treatment for each genotype, the number of Peg-IFN or
RBV units per week and the percentage of patients who
completed their treatment (80% in most countries unless
stated otherwise). The annual number of units was
© 2015 John Wiley & Sons Ltd
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adjusted using inputs from the expert panel to account for
uses other than HCV as well as potential under-reporting.
RESULTS
Table 1 includes the results of the literature review for all
15 countries in this analysis, including estimates of anti-
body and viraemic prevalence, genotype distribution, virae-
mic diagnosis, annual treatment and liver transplants. The
specific age and gender distribution of the viraemic-preva-
lent population for each country is shown in Fig. 1.
Estonia
HCV-infected population
HCV epidemiology data are sparse in Estonia. The preva-
lence of anti-HCV was estimated between 1.5% and 2.4%,
in 2013, with a viraemic prevalence of 1.5% (1.1–1.9%)
(expert consensus). The viraemic rate was estimated
through expert consensus to be 76%. The age and gender
distribution was estimated using annual notification data
from 2000 to 2013 [16]. The notified population was aged
to the year 2013, accounting for mortality and cured
patients. Multiple genotype studies were available, with the
most recent estimate chosen for consideration in the model
[17].
Diagnosed
As of 2014, approximately 9600 viraemic cases were diag-
nosed (50%) (expert consensus). Annually, 190 viraemic
cases are newly diagnosed [16].
Treated
In 2014, approximately 500 patients were treated for HCV.
Of these, 34 ≥F3 patients were treated with boceprevir, 39
≥F3 patients were treated with telaprevir, and the remainder
of patients ≥F0 were treated with Peg-IFN/Riba [18].
Liver transplants
Data on the annual number of liver transplants and liver
transplants attributable to HCV were available from the
Transplantation Centre of Tartu University Hospital. Tartu
University Hospital is the only hospital in Estonia where
organ transplants are performed. In 2014, 10 liver trans-
plants were performed, with four (40%) attributable to
HCV.
Hungary
HCV-infected population
HCV epidemiology data are sparse in Hungary. The preva-
lence of anti-HCV was estimated at 0.70% (0.5–0.9%)
based on expert consensus. A viraemic rate of 75%, pro-
vided by experts, was applied. The total viraemic popula-
tion in 2014 was estimated at 52 000 (39 000–65 000)
individuals, corresponding to a viraemic prevalence of
0.5% (0.4–0.7%). The age and gender distribution of the
infected population was constructed using unpublished
data from the Hungary treatment registry, which was pro-
vided through personal communication with experts
(Makara 2015 personal communication). The genotype
distribution in the prevalent population was estimated
using data from both non-IDU and IDU sources. The non-
IDU genotype distribution was based on data presented at
the 8th International Symposium on Molecular Diagnostics
[19], with adjustment based on expert consensus to the
distribution of G1 and G3. The genotype distribution for
IDU was based on personal communication with experts
(Makara 2015 personal communication) and was propor-
tionally combined with the non-IDU genotype distribution
to calculate a weighted overall distribution for the preva-
lent population.
Diagnosed
Estimates of the diagnosed population were based upon
expert consensus. There were an estimated 20 900 previ-
ously diagnosed cases in 2010 and 2100 newly diagnosed
cases.
Treated
According to expert input, it was estimated that between
1000 and 1200 patients were treated annually.
Liver transplants
Liver transplant data were available through an interna-
tional organ registry for the years 1993 to 2013 [20]. In
2013, there were 45 liver transplants performed in Hun-
gary. According to expert consensus, the number of liver
transplants jumped to 70 in 2014. Experts estimate that
30% of liver transplants per year are attributable to HCV.
Iceland
HCV-infected population
Overall prevalence of anti-HCV in 2014 was estimated at
0.4% (0.3–0.5%). Based on expert consensus, approximately
80% of HCV cases have been diagnosed in Iceland. The total
number of surviving diagnosed anti-HCV cases, excluding
previously treated and cured patients, is estimated at 1080
based on data from the Centre for Health Security and Infec-
tious Disease Control, equivalent to approximately 1400
prevalent cases after adjustment for the undiagnosed popula-
tion. A viraemic rate of 80% was applied, and the total virae-
mic population in 2014 was estimated at 1100 (880–1300)
individuals after accounting for treated and cured patients,
corresponding to a viraemic prevalence of 0.3% (0.3–0.4%).
Data from the Centre for Health Security and Infectious Dis-
ease Control were used to determine the age and gender dis-
tribution based on demographic data collected from surviving
diagnosed cases during 1986 to August 2014. The genotype
© 2015 John Wiley & Sons Ltd
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Fig. 1 Viraemic hepatitis C virus (HCV) prevalence by age and gender.
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distribution of the prevalent population was estimated using
unpublished laboratory data from 494 cases in Iceland col-
lected by the Department of Virology at Landspitali University
Hospital, while the distribution of G1 subtypes was based on
data from the same source during an earlier time period.
Diagnosed
The total number of anti-HCV diagnosed cases is estimated
at 1230, with 865 diagnosed after adjustment for mortal-
ity, viraemia and treated and cured. The newly diagnosed
population in 2013 was estimated at 70, with approxi-
mately 60 newly diagnosed after adjustment for viraemia.
Treated
It was estimated that 25–30 patients were treated annually
based on overall treatment levels between 2002 and 2012,
during which a total of 207 patients received treatment.
Liver transplants
From 1985 to 2013, a total of 45 patients underwent liver
transplantation in Iceland. Two transplants during this
time period were attributable to HCV (4%).
Indonesia
HCV-infected population
The 2007 anti-HCV prevalence was estimated to be
0.8% (range 0.1% in Sumatra Barat to 1.7% in Nang-
groe Aceh Darussalam), using the National Basic Health
Research (RISKESDAS) 2007 study [21]. The viraemic rate
was estimated to be 66% based on an older study [22]; how-
ever, this estimate is in line with more recent unpublished
estimates (expert consensus). This corresponds to a viraemic
prevalence of 0.5% (0.1–1.1%) in 2007, or 1 214 000
(182 000–2 534 000) infected individuals. The age and gen-
der distribution was estimated using data from RISKESDAS
2007 [21]; however, it is important to note that the data are
from the West and middle of Indonesia and are not necessar-
ily representative of the entire country. Genotype 1 predomi-
nates in Indonesia, followed by G3. The genotype distribution
(G1: 68%, G2: 9%, G3: 9%, G4: 4%, G other: 10%) was deter-
mined by averaging genotypes from three unpublished data
sources, including a study in HIV-coinfected patients to
account for under-represented populations (Lesmana, Mul-
jono and Yunihastuti 2015 personal communications).
Fig. 1 (continued)
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Diagnosed
Based on Indonesian Red Cross data and expert consensus,
there were estimated to be 121 000 viraemic individuals
(approximately 10% of the viraemic-prevalent population)
with a known diagnosis of chronic HCV in 2013. Between
2007 and 2009, the Ministry of Health reported approxi-
mately 18 000 individuals diagnosed with HCV. Applying
this annual number of diagnosed cases to the years 1992–
2007 would suggest that by 2009 a total of 90 000 anti-
HCV or 59 100 viraemic individuals had been diagnosed.
Additionally, from 2010 until 2014, The Indonesian Red
Cross notified between 8400 and 12 100 individuals of an
HCV diagnosis annually through blood donation, or
approximately 35 500 viraemic-diagnosed individuals and
notified over five years (Syafitri 2015 personal communica-
tion). Overall, this suggests a total of 94 600 diagnosed
and reported viraemic cases. Considering that some diag-
nosed cases would not be reported to the Ministry of
Health or via blood donation, an overall diagnosis rate of
10% was estimated at approximately three times the num-
ber of known diagnosed cases. Approximately 12 100 vir-
aemic cases were newly diagnosed annually, based on an
estimate of 11 000 known cases and assuming a small
number of unreported cases.
Treated
It was estimated that 230 patients were treated annually
based on IMS data for standard units of Peg-IFN sold after
adjustment to account for under-reporting and increased
treatment of genotype 2 patients.
Liver transplants
Liver transplants are uncommon in Indonesia, as many
patients travel abroad for a transplant. In one large hospi-
tal in Jakarta, there have been a total of 13 liver trans-
plants performed (Gani 2015 personal communication).
None of the patients treated were infected with HCV (Gani
2015 personal communication).
Iran
HCV-infected population
In 2006, a population-based study across three provinces
estimated the antibody prevalence of HCV in adults aged
18–65 to be 0.5% [23]. When adjusted to include all ages,
the anti-HCV prevalence in Iran is estimated to be 0.4%
(0.3–0.5%), representing 275 000 (189 000–360 000)
individuals in 2006. Utilizing a widely published viraemic
rate of 62%, there is a viraemic prevalence of 0.2% (0.2–
0.3%) representing approximately 170 000 (117 000–
223 000) viraemic persons in 2006 [24]. The population-
based study provided a reliable age and gender distribution
[23]. Where data were lacking for the age and gender dis-
tribution, expert consensus was utilized. In Iran, the domi-
nant genotype is 1, followed by genotype 3 [25].
Diagnosed
Based on expert opinion, it was estimated that there are
60 000 individuals diagnosed with HCV in Iran in 2013.
It is estimated that there are 6000 individuals newly diag-
nosed annually.
Treated
Through expert consensus, it was estimated that there
were 4500 individuals treated for HCV in 2011.
Liver transplants
Actual liver transplant data were available through IRO-
DaT, with 590 liver transplants occurring in 2013. In
Iran, 16% of all liver transplants are due to HCV, corre-
sponding to 94 HCV-related liver transplants in 2013 [26].
Japan
HCV-infected population
The viraemic-prevalent population in 2011 was estimated
to range from 1 010 000 to 1 510 000 individuals (equiva-
lent to a viraemic prevalence of 0.8–1.2%). Based on ratios
between base, high and low viraemic prevalence reported
for 2005 [27], the base viraemic prevalence in 2011 was
estimated at 1.0% (1 252 000 cases). With a viraemic rate
of 70% [28], anti-HCV prevalence in 2011 was estimated at
1.4% (1 789 000 cases). The age and gender distribution
of the infected population in 2005 was based on reported
prevalence rates among individuals aged 5–74 years [27].
It was assumed that prevalence in the 0–4 year age group
was equal to that of 5- to 9-year-olds. Prevalence among
individuals aged 75+ years was assumed to increase as
compared to younger individuals based on a trend of
increasing prevalence with age. A male/female ratio of 0.96
was applied based on reported prevalence rates by gender
[28]. The genotype distribution of the prevalent population
was estimated using laboratory data from 494 cases in
Japan, while the distribution of G1 subtypes was based on
data from the same source during an earlier time period.
Diagnosed
The total number of viraemic undiagnosed cases was esti-
mated at 296 000 cases in 2011 [27]. With 1 252 000
viraemic cases in 2011, the previously diagnosed viraemic
population was estimated at 956 000. Based on expert
consensus, the newly diagnosed viraemic population in
2014 is estimated at 8000.
Treated
Based on IMS unit for Peg-IFN sold in 2012, it was esti-
mated that 26 900 patients were treated annually.
Liver transplants
Total annual liver transplants from 1989 to 2011 were
reported by the Japanese Liver Transplantation Society
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[29]. The proportion attributable to HCV varied by year
and ranged from 0% to 54%. In 2011, there were an esti-
mated 219 liver transplants attributable to HCV.
Latvia
HCV-infected population
A 2008 population-based study in Latvia identified an
anti-HCV prevalence of 2.4% (95% CI 1.7–3.3%) in the
general population [30]. These data also suggest a virae-
mic rate of 71%, corresponding to a 1.8% (1.2–2.4%)
viraemic prevalence in the total population (39 000 in
2008) [30]. The age and gender distribution was estimated
using annual notification data from 2010 to 2014 (partial
year 2014) [31]. The notified populations was aged to the
year 2013, accounting for mortality and cured patients.
Diagnosed
As of 2008, approximately 17 000 of the 39 000 viraemic
cases were diagnosed (42.5%) [32]. From 2010 to 2014,
an average of 1300 chronic HCV cases were newly diag-
nosed [33].
Treated
In 2014, approximately 840 patients were treated for HCV
with Peg-IFN and RBV. The number of patients treated
annually between 2011 and 2014 was available from the
National Health Service [34]. Additionally, the number of
patients treated annually at the Infectology Center of Lat-
via was available for 2005–2014 (Tolmane 2015 personal
communication).
Liver transplants
Liver transplants are not reimbursed by the government,
and there has only been one liver transplant ever conducted
in Latvia [20,32]. A long waiting list exists for transplants,
and some patients (including children) have chosen to tra-
vel abroad for the procedure (expert consensus).
Lebanon
HCV-infected population
The most up-to-date data from 2010 to 2011 report an
anti-HCV prevalence of 0.2% among all ages in the general
population in Lebanon [35]. Low (0.1%) and high (0.7%)
prevalence estimates were chosen from the literature
[36,37]. A viraemic prevalence of 0.2% (0.1–0.6%) was
calculated using the viraemic rate of 85% from the same
study [35], corresponding with 7900 (2800–28 000) vir-
aemic cases in 2011. The general population study was
used to apply an age distribution and male-to-female ratio
[35]. Unpublished data on 1030 HCV-infected patients
from 2012 to 2013 determined the genotype distribution
between genotypes 1 and 4, but the G1 subtype distribu-
tion came from a 2007 study [38].
Diagnosed
Data on number of HCV cases diagnosed in Lebanon are
sparse. The Ministry of Health reports incomplete data, and
there is no published literature on the annual number of
diagnosed cases. Experts estimated that approximately 20%
of all viraemic cases have been diagnosed, with 2% of vir-
aemic cases diagnosed each year. This corresponds to
approximately 1600 previously diagnosed cases and 160
newly diagnosed cases annually in 2014.
Treated
Data were obtained from the Ministry of Public Health on
number of patients treated in 2013–2014, and expert input
estimated this accounted for approximately 45% of all trea-
ted cases. Pharmaceutical audit data were used to estimate
number treated from 2007 to 2012. It was estimated that
280 patients were treated in 2013 and 170 in 2014.
Liver transplants
Liver transplants are very rare in Lebanon. Data from the
one hospital that performs transplants reported 15 trans-
plants between 1999 and 2008, with only one due to HCV
(6.7%) [39,40]. Experts estimate an additional 6–8 trans-
plants were performed on Lebanese patients each year in
foreign countries. Four transplants were performed and
reported in Lebanon in 2013 [20].
Lithuania
HCV-infected population
A national seroprevalence survey was underway in Lithua-
nia in 2010–2013. Although initial results from 2010
(anti-HCV prevalence of 2.85% among adults) have been
published [41], there has been concern that the individuals
seeking free testing in this first year were more likely to be
at high risk of infection (Liakina 2015 personal communi-
cation). Preliminary results including 2010 and going
through 2013 are currently unpublished but suggest an
anti-HCV prevalence of 1.96% (1.21–2.71%) in adults 18–
81 years of age (Liakina 2015 personal communication).
When extrapolated to the entire population (all ages), an
overall estimated anti-HCV prevalence of 1.7% (1.0–2.3%)
was considered for 2013. These data also suggest a virae-
mic rate of 66%, corresponding to a 1.29% viraemic preva-
lence among adults 18–79 years, or 1.1% (0.7–1.5%) in
the total population (33 000 in 2013) (Liakina 2015 per-
sonal communication). The age distribution was informed
by initial 2010 results (5-year age-cohort) [41] and unpub-
lished 2010–2013 results (average age of 47  16 years)
(Liakina 2015 personal communication). Approximately
54% of anti-HCV-positive individuals are male [41]. Of
note, unpublished results suggest asymptomatic HCV-RNA
carriers were younger (38.3  15.5 years) and more
evenly distributed by gender (52.6% males), as compared
with the anti-HCV-positive population.
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The 2003–2009 genotype distribution was estimated
using data from 125 treatment na€ıve patients enrolled in
the chronic hepatitis C cohort [42]. Additionally, the geno-
type 1a/1b split was available from 2000 patients admitted
for antiviral treatment to the Center of Hepatology, Gas-
troenterology and Dietetics at Vilnius University Hospital
Santariskiuz Klinikos between 1996 and 2006 [43].
Diagnosed
Estimates of the diagnosed and newly diagnosed popula-
tions were unavailable, so the percentage of diagnosed
cases in Poland (15%) in 2010 was chosen as an analogue,
with 10% newly diagnosed annually (expert consensus).
This corresponds to approximately 5000 total diagnosed
and 500 annual newly diagnosed cases in 2010.
Treated
Accurate estimates of treated patients were not available;
however, expert opinion suggested that between 300 and
600 patients have been treated annually since 2004
(Valantinas 2015 personal communication). The mid-point
of 450 patients was chosen for the model.
Liver transplants
The annual number of liver transplants was available from
IRODaT from 2002 to 2014 [20,44]. Of the 101 total liver
transplants performed in Lithuania, 40 (40%) were attribu-
table to HCV (Valantinas 2015 personal communication).
Pakistan
HCV-infected population
Pakistan has previously been identified as one of the three
countries with the highest number of viraemic HCV infec-
tions in the world [45]. In 2008, there was a nationwide
estimate on antibody prevalence of HCV infection corre-
sponding to 4.8% [46]. A range of 3.5–5.9% was chosen
by expert opinion. This rate corresponds to 8 010 000
(5 792 000–9 920 000) individuals infected with HCV in
2008. Utilizing a widely published viraemic rate of 87.4%,
there is a viraemic prevalence of 4.2% (3.0–5.2%), repre-
senting approximately 7 001 000 (5 062 000–8 670 000)
viraemic persons in 2008 [47]. The data from the afore-
mentioned national study also provided a reliable age and
gender distribution for the infected population. Data from a
systematic review of 34 papers published between 1996
and 2011 were used to establish the genotype distribution
[48].
Diagnosed
Based on expert opinion, it was estimated that 15% of the
viraemic HCV-infected population had been diagnosed in
2010, corresponding to approximately 1 050 000 virae-
mic-diagnosed individuals. It is estimated that there are
100 000 individuals newly diagnosed annually.
Treated
It was estimated that there were 85 000 individuals trea-
ted in 2011. This was based on an analysis of standard
and Peg-IFN units sold in Pakistan.
Liver transplants
Based on expert opinion, it is estimated that an annual
300 Pakistanis receive liver transplantation both domesti-
cally and abroad, with 75% of these transplants attributed
to HCV [49,50].
Romania
HCV-infected population
The most recent HCV prevalence estimate in Romania was
3.23%, or 529 100 anti-HCV cases, among adults aged
18–69 in 2008 [51]. This estimate, applied to the entire
population, increases to an anti-HCV prevalence of approx-
imately 3.3%, or 719 000 cases. An anti-HCV prevalence
range of 2.9–3.6% was chosen by expert input. A virae-
mic rate of 85% was determined by expert consensus, cor-
responding to a viraemic prevalence of 2.8% (2.5–3.1%)
and 611 000 (541 000–680 000) viraemic cases in
2008. A nationwide study of the adult population deter-
mined the age distribution for 18- to 69-year-olds [51],
and experts estimated that the prevalence rate would
remain at the rate for 60- to 69-year-olds for adults over
the age of 70. Based on expert consensus, the rates for
the younger age groups (10–14, 5–9, 0–4) decreased by
25% with each successive age group. A genotype distribu-
tion study from 241 viraemic individuals from 2004 to
2008 found that the vast majority of cases were type 1b,
followed by type 1a [52]. Only 1.20% of cases were found
to be genotype 4, and 0.8% of cases were found to be
genotype 3 [52].
Diagnosed
Based on expert consensus, there are an estimated 7500
viraemic cases diagnosed per year in Romania, and there
have been an estimated 90 000 previously diagnosed
cases.
Treated
In 2014, approximately 4100 new patients were treated
in Romania, which is the lowest number of treatment ini-
tiations in the country since 2007 (Gheorghe 2015 per-
sonal communication). In 2013, for example, 6086
treatments were initiated (Gheorghe 2015 personal com-
munication).
Liver transplants
Liver transplant data for 2000–2013 were available
through the International Registry for Organ Donation and
Transplantation and the Romania National Transplant
Agency [20,44,53]. Expert consensus determined that the
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number of liver transplants in 2014 was 124, a slight
increase from the reported 122 transplants in 2013.
Between 2000 and 2011, 27% of transplants in Romania
were attributable to HCV [54].
Saudi Arabia
HCV-infected population
The prevalence rate of anti-HCV in Saudi nationals aged
≥15 years was estimated at 1.08% (0.97–1.19%) based on
expert consensus, with a much lower prevalence rate
among children (0.19%). Overall, the prevalence in Saudi
nationals was estimated to be 0.7% (0.6–0.9%). A viraemic
rate of 70% was applied [55], resulting in a viraemic
prevalence rate of 0.5% (0.4–1.3%) among all ages and a
total viraemic population of approximately 100 000
(81 000–257 000) individuals in 2011. The age distribu-
tion was based on data from 28 000+ blood units collected
in a donor study conducted in the Jazan region from 2004
to 2009 [56] and then modified via expert input, specifi-
cally regarding ages >60 years. A male/female ratio based
on a prevalence study of 1482 subjects in the Gizan area
screened for HCV [57] was applied. Genotype distribution
was applied from a meta-analysis of 18 genotype studies in
Saudi Arabia [58] with genotype 1 subtype estimates pro-
vided by expert consensus.
Diagnosed
Data on the number of diagnosed HCV cases in Saudi Ara-
bia are limited. The percentage of viraemic cases previously
diagnosed was estimated at 20% in 2013 based on expert
input. Cases newly diagnosed in 2013 were estimated to
account for 10% of those previously diagnosed cases, or
3% of all viraemic cases. Thus, the total number diagnosed
in 2013 was estimated to be 20 100 cases, with 2010 of
those newly diagnosed that year.
Treated
It was estimated that 1900 Saudi nationals were treated
annually in 2009 based on expert input and adjusting for
immigrant patients. IMS data for standard units of Peg-IFN
sold were used to estimate number treated from 2006 to
2009. The standard treatment in Saudi Arabia as of 2014
was Peg-IFN and ribavirin.
Liver transplants
In 2012, there were 146 liver transplants performed in
Saudi Arabia according to data collected at a national
organ transplantation centre from 1990 to 2012 [59]. It
was estimated that 98% of these transplants were per-
formed on Saudi nationals based on expert input. Nearly
half of all liver transplants in Saudi Arabia were attribu-
table to patients with HCV according to expert consen-
sus.
Slovenia
HCV-infected population
The real HCV prevalence remains unknown in Slovenia as
no national survey has been performed. HCV prevalence in
the total population was estimated at 0.4% (0.3–0.5%) based
on expert input. A study of 72% of all patients who were
diagnosed with chronic HCV in Slovenia from 1993 to 2007
found a viraemic rate of 78% in 2007 [60], corresponding to
a viraemic prevalence of 0.3% (0.2–0.4%), or 6500 (4900–
8100) viraemic cases in 2014. The age and gender distribu-
tion was developed using data from the 1993–2007 study
analysing 1504 serum samples (72.6% of all the patients
diagnosed with hepatitis C in that period) that had been col-
lected and processed on the national level at the referential
laboratory for viral hepatitis of the Medical Faculty University
of Ljubljana [60]. The highest rate of anti-HCV prevalence
was found in 21- to 30-year-olds, and there was an overall
ratio of 67.3% males to 32.7% females [60]. The genotype
distribution of the infected population was also derived from
the 1993–2007 study, with the majority of cases testing as
genotypes 1 and 3 [60]. Ratios of genotype 1 subtypes 1a to
1b were determined using data from a study on pregnant
women in Slovenia in 1993, 2003, 2009 and 2013 and
were applied to the 1993–2007 genotype data [60,61].
Diagnosed
Expert consensus during a 2015 National Viral Hepatitis
Expert Group panel in Slovenia estimated the number of
previously diagnosed viraemic cases to be 3300 (Maticic
2015 personal communication). It is estimated that 5% of
total diagnosed cases, or approximately 170 cases, are
newly diagnosed each year.
Treated
HCV treatment in Slovenia is performed at five treatment
centres in five regions of Slovenia, with the Clinic for Infec-
tious Diseases and Febrile Illnesses at the University Medi-
cal Centre Ljubljana representing the referential centre.
The National Viral Hepatitis Expert Group set up consensus
guidelines for HCV treatment in 1997 and has been updat-
ing them regarding the Standard of Care [62]. The data on
all the treated patients in Slovenia regarding treatment
efficacy and safety have been collected and periodically
analysed since 1997 [63,64]. The 2015 National Viral
Hepatitis Expert Group panel came to the consensus that
1700 patients had already been treated as of March 2015
(Maticic 2015 personal communication). The number of
treated patients in 2014 was estimated to be 150, based
on expert input.
Liver transplants
Unpublished national liver transplant data between 1998
and 2014 from the National Viral Hepatitis Expert Group
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indicate that approximately 7% of liver transplants during
this period were attributable to HCV (Maticic 2015 per-
sonal communication). In 2014, there were 31 liver trans-
plants performed, an increase of 35% from the highest
number of transplants performed in recent years (Maticic
2015 personal communication).
South Korea
HCV-infected population
The most recent estimate of anti-HCV prevalence among
adults was 1.2% in 2013, a slight reduction from 1.29%
in 2009 [65]. This corresponds to 1.0% prevalence in the
general population. Low (0.8%) and high (1.3%) preva-
lence estimates were chosen from the literature [65,66]
The viraemic rate was estimated to be 56%, corresponding
to a viraemic prevalence of 0.6% (0.4–0.7%) in 2009 and
268 000 (211 000–349 000) infected individuals [66].
The age and gender distribution was estimated from a
nationwide seroepidemiology survey of adults ≥20 years,
in which the average age was 54 years [66]. For children
and adolescents under 20 years of age, an accelerated
reduction in prevalence was assumed. The genotype distri-
bution was established from a study of 930 patients in the
HCV cohort [67].
Diagnosed
As of 2012, approximately 93 600 viraemic cases were
diagnosed (35%) (expert consensus). Annually, 8000 vir-
aemic cases (3% of the total population) are newly diag-
nosed (expert consensus).
Treated
It was estimated that 4500 patients annually were trea-
ted based on expert consensus and IMS data for standard
units of Peg-IFN sold after adjustment to account for
under-reporting and increased treatment of genotype 2
patients.
Liver transplants
Liver transplant data for 2000–2011 were available
through the Korean Network for Organ Sharing [68]. Prior
to 2000, the number of transplants and percentage of trans-
plants attributable to HCV (2.5%) were available through
published estimates [69]. Indications for liver transplant
were available from 2009 to 2013 through the Korean Net-
work for Organ Sharing, which suggests that approximately
5% of liver transplants were attributable to HCV [68].
UAE
HCV-infected population
HCV epidemiology data are limited in the United Arab Emi-
rates (UAE). Expert consensus estimates the prevalence of
anti-HCV to be 1.5% (1.4–1.7%) among all ages of UAE
nationals. A viraemic rate of 68% [70] was applied, result-
ing in a total viraemic population estimate of 11 000 (10
000 – 12 000) and a viraemic prevalence rate of 1.0%
(0.9–1.1%) among UAE nationals. In the absence of data
on age distribution, analogue data were used from
28 000+ blood units collected in a donor study conducted
in Saudi Arabia from 2004 to 2009 to estimate the age
distribution [71]. Based on expert input, age distribution
was modified to peak around age 45 years and remained
at a constant rate from that age forward. A male/female
ratio was applied using unpublished data from Mafraq hos-
pital in Abu Dhabi. Genotype distribution (including geno-
type 1 subtypes) was determined by aggregating data from
a study of 124 UAE nationals in Dubai [72] and unpub-
lished data from a hospital in Abu Dhabi and weighted by
regional population.
Diagnosed
Expert consensus estimates that one-third of the viraemic
population had been diagnosed in 2014. Using analogue
data from Egypt, approximately 3% of viraemic cases were
newly diagnosed in the same year [7]. It was estimated
that a total of 3600 UAE citizens had been diagnosed as of
2014, including 360 newly diagnosed cases that year.
Treated
It was estimated that 140 patients were treated annually
from 2011 based on expert consensus.
Liver transplants
Expert consensus approximates that around 30 liver trans-
plants are performed each year with 20 of those performed
on nationals. Experts estimate 60% of liver transplants are
due to HCV.
DISCUSSION
This analysis was designed to develop consensus estimates
for the epidemiology of HCV infection in the countries
under study. Published data from each country were iden-
tified through an initial literature search. Those results
were then discussed and reviewed with an expert advisory
panel in each country. Where possible, the members of the
advisory panel also provided additional data including hos-
pital and national-level data as well as unpublished study
data. This method of developing consensus estimates
allowed for a more complete picture of HCV epidemiology
to be developed, even in countries where national preva-
lence studies may not yet have been performed. In-depth
review of all data with an advisory panel of experts in the
field of HCV within each country also increased the accu-
racy of each analysis.
Given the substantial global disease burden associated
with HCV, it is imperative that reliable epidemiological
data are available so that policy makers can make the
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most informed decisions possible for their respective coun-
tries. As higher efficacy treatments (SVR > 90%) with
fewer side effects and shorter treatment durations become
available, countries are faced with challenging public
health policy questions about changing national treat-
ment paradigms, such as the impact of limiting treatment
to patients in certain disease stages. Data from this study
can be used by researchers and policy makers to examine
how best to combat HCV through further disease burden
modelling, analysis of risk factors including the impact of
immigration, and the creation of the most appropriate
prevention, screening and treatment strategies.
Anti-HCV prevalence estimates in the countries
represented in this study range from as low as 0.2% of the
population in Lebanon to 4.8% in Pakistan. Figure 1
shows the age and gender distribution of HCV prevalence
in each country. Examining the distribution in this manner
allows for an analysis of the main risk factors associated
with HCV infection. Countries where injection drug use
(IDU) is the main source of new HCV infections (e.g. Ice-
land, Iran and Slovenia) generally display a higher preva-
lence in men of younger age groups, whereas countries
where infection was historically related to an unsafe blood
supply or nosocomial transmission (e.g. Japan, Pakistan
and South Korea) generally display a higher prevalence in
older age groups. Genotype distribution also varied widely
between countries. This heterogeneity in genotype distribu-
tion is observed even among the countries in one region,
which mainly reflects differences in HCV epidemiology,
modes of transmission and ethnic variability. For example,
Genotype 1 is the most common genotype in Iran, while
Genotype 3 is prominent in Pakistan and Genotype 4 is
the most common genotype in Saudi Arabia. Overall,
Genotype 1 is the most common, accounting for over 80%
of cases in some countries. However, it is difficult to make
comparisons of genotype, age and gender distributions
across countries, as estimates from the literature span a
period of over 20 years. Comparison of HCV epidemiology
across all countries in 2014 is the subject of another paper
in this supplement [13].
Although a prevalence estimate was gathered for every
country, the quality of estimates varied. A quantitative
scoring system [73] was not used to compare the quality
of prevalence figures, but national surveillance and general
population studies in Indonesia, Latvia, Lebanon, Lithua-
nia, Pakistan and Romania were more robust than consen-
sus estimates. While the development of consensus
estimates provides the best estimates of HCV epidemiology
through the combination of all available data and expertise
within a specific country, this method also has the poten-
tial for some biases. In countries where limited or no data
were available, the estimates used in this analysis were
based on the consensus of the advisory panel and therefore
may not accurately represent the actual HCV epidemic in
the country.
Furthermore, data used from registries or specific epi-
demiological studies may introduce a selection bias to this
analysis, as testing and reporting may not be consistent
across all subpopulations and would likely not be represen-
tative of hard-to-sample populations such as IDU.
It is important to note that the viraemic rate and geno-
type distributions often came from studies with small sam-
ple sizes, and in many countries, the genotype distribution
is rapidly changing due to differences in historical risk fac-
tors compared to the risk factors currently driving the epi-
demic.
When data were not available for the number of treated
patients within a country, estimates were based on drug
sales data. In the absence of better information, the esti-
mated number of treated patients by genotype was deter-
mined using the genotype distribution of the infected
population. In some cases, these estimates still might be
over- or under-estimates of the true treatment numbers
genotype as some genotypes may be preferentially treated.
While this analysis is based on the best available data,
the limitations inherent in these consensus estimates
underscores the need for additional research to be con-
ducted to further estimate the true HCV burden among
both the general population and specific subpopulations
who might be missed in a national study.
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